DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis

Information source: Allergan
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Conjunctivitis, Allergic

Intervention: AGN-229666 (Drug); Vehicle to AGN-229666 (Drug); Olopatadine (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Allergan

Official(s) and/or principal investigator(s):
Medical Director, Study Director, Affiliation: Allergan


This study will evaluate the safety and efficacy of AGN-229666 for the prevention of allergen-mediated conjunctivitis.

Clinical Details

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention

Primary outcome: Ocular Itching Score Using a 6-Point Scale

Secondary outcome: Conjunctival Hyperemia Score Using a 9-Point Scale


Minimum age: 20 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Japanese patients living in Japan with a history of allergic conjunctivitis.

Exclusion Criteria:

- Presence of active eye infection (bacterial, viral, or fungal)

- History of an eye herpetic infection.

Locations and Contacts

Tokyo, Japan
Additional Information

Starting date: June 2014
Last updated: January 15, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017